Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
af Björkesten, Clas-Göran; Ilus, Tuire; Hallinen, Taru; Soini, Erkki; Eberl, Anja; Hakala, Kalle; Heikura, Mikko; Jussila, Airi; Koskela, Ritva; Koskinen, Inka; Moilanen, Veikko; Nielsen, Christian; Nieminen, Urpo; Nuutinen, Heikki; Heikkinen, Markku; Suhonen, Ulla-Maija; Tillonen, Jyrki; Utriainen, Karri; Vihriälä, Ilkka; Wennerström, Christina; Borsi, Andras; Nissinen, Riikka; Koivunen, Minni R.; Sipponen, Taina (2020-12-01)
af Björkesten, Clas-Görana; Ilus, Tuireb; Hallinen, Taruc; Soini, Erkkic; Eberl, Anjaa; Hakala, Kalled; Heikura, Mikkoe; Jussila, Airib; Koskela, Ritvaf; Koskinen, Inkag; Moilanen, Veikkoh; Nielsen, Christiani; Nieminen, Urpoa; Nuutinen, Heikkij; Heikkinen, Markkuk; Suhonen, Ulla-Maijal; Tillonen, Jyrkim; Utriainen, Karrin; Vihriälä, Ilkkao; Wennerström, Christinap,,q; Borsi, Andrasr; Nissinen, Riikkas; Koivunen, Minni R.s; Sipponen, Tainaa Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort, European Journal of Gastroenterology & Hepatology: December 2020 - Volume 32 - Issue 12 - p 1507-1513 doi: 10.1097/MEG.0000000000001831
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://urn.fi/URN:NBN:fi-fe202101202190
Tiivistelmä
Abstract
Objective: Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn’s disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn’s disease patients treated with ustekinumab.
Methods: The study was conducted in 17 Finnish hospitals and included adult Crohn’s disease patients who received an initial intravenous dose of ustekinumab during 2017–2018. Disease activity data were collected at baseline, 16 weeks, and 1 year from health records.
Results: The study included 155 patients. The disease was stricturing or penetrating in 69 and 59% had prior Crohn’s disease-related surgeries, and 97% had a treatment history of at least one biologic agent. Of 93 patients with ≥1 year of follow-up, 77 (83%) were still on ustekinumab at 1 year. In patients with data available, from baseline to the 1-year follow-up the simple endoscopic score for Crohn’s disease (SES-CD) decreased from 10 to 3 (P = 0.033), C-reactive protein from 7 to 5 mg/L, (P < 0.001) and faecal calprotectin from 776 to 305 μg/g (P < 0.001).
Conclusions: Ustekinumab treatment in patients with highly refractory Crohn’s disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity.
Kokoelmat
- Avoin saatavuus [31992]
Samankaltainen aineisto
Näytetään aineisto, joilla on samankaltaisia nimekkeitä, tekijöitä tai asiasanoja.
-
Modeling rare human disorders in mice : the Finnish disease heritage
Zárybnický, Tomáš; Heikkinen, Anne; Kangas, Salla M.; Karikoski, Marika; Martínez-Nieto, Guillermo Antonio; Salo, Miia H.; Uusimaa, Johanna; Vuolteenaho, Reetta; Hinttala, Reetta; Sipilä, Petra; Kuure, Satu
Cells : 11 (Multidisciplinary Digital Publishing Institute, 13.11.2021) -
Association of biallelic <em>RFC1</em> expansion with early-onset Parkinson’s disease
Ylikotila, Pauli; Sipilä, Jussi; Alapirtti, Tiina; Ahmasalo, Riitta; Koshimizu, Eriko; Miyatake, Satoko; Hurme-Niiranen, Anri; Siitonen, Ari; Doi, Hiroshi; Tanaka, Fumiaki; Matsumoto, Naomichi; Majamaa, Kari; Kytövuori, Laura
European journal of neurology : 5 (John Wiley & Sons, 12.02.2023) -
Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological/neurodegenerative diseases
Karagianni, Korina; Bibi, Alessia; Madé, Alisia; Acharya, Shubhra; Parkkonen, Mikko; Barbalata, Teodora; Srivastava, Prashant K; de Gonzalo-Calvo, David; Emanueli, Constanza; Martelli, Fabio; Devaux, Yvan; Dafou, Dimitra; Nossent, A Yaël; ,
Molecular therapy nucleic acids : 1 (Elsevier, 19.12.2023)